IPH Fundamental Analysis - INNATE PHARMA SA

Fundamental Rating

Overall IPH gets a fundamental rating of 1 out of 10. We evaluated IPH against 82 industry peers in the Biotechnology industry. Both the profitability and financial health of IPH have multiple concerns. IPH is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IPH has reported negative net income.

IPH had a negative operating cash flow in the past year.

In the past 5 years IPH always reported negative net income.

In the past 5 years IPH always reported negative operating cash flow.

1.2 Ratios

IPH has a worse Return On Assets (-49.46%) than 65.85% of its industry peers.

IPH's Return On Equity of -894.94% is on the low side compared to the rest of the industry. IPH is outperformed by 70.73% of its industry peers.

		Industry Rank	Sector Rank
ROA	-49.46%
ROE	-894.94%
ROIC	N/A

ROA(3y)-25.47%

ROA(5y)-23.4%

ROE(3y)-225.59%

ROE(5y)-153.39%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 49.52%, IPH is in line with its industry, outperforming 48.78% of the companies in the same industry.

IPH's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for IPH so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	49.52%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.49%

GM growth 5Y-4.49%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IPH does not have a ROIC to compare to the WACC, probably because it is not profitable.

IPH has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, IPH has more shares outstanding

IPH has a worse debt/assets ratio than last year.

2.2 Solvency

IPH has an Altman-Z score of -6.39. This is a bad value and indicates that IPH is not financially healthy and even has some risk of bankruptcy.

IPH has a Altman-Z score of -6.39. This is in the lower half of the industry: IPH underperforms 74.39% of its industry peers.

IPH has a Debt/Equity ratio of 11.63. This is a high value indicating a heavy dependency on external financing.

The Debt to Equity ratio of IPH (11.63) is worse than 70.73% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	11.63
Debt/FCF	N/A
Altman-Z	-6.39

ROIC/WACCN/A

WACC6.46%

2.3 Liquidity

IPH has a Current Ratio of 2.24. This indicates that IPH is financially healthy and has no problem in meeting its short term obligations.

IPH has a Current ratio (2.24) which is comparable to the rest of the industry.

IPH has a Quick Ratio of 2.24. This indicates that IPH is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of IPH (2.24) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.24
Quick Ratio	2.24

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.32%.

Looking at the last year, IPH shows a very negative growth in Revenue. The Revenue has decreased by -75.86% in the last year.

The Revenue for IPH have been decreasing by -28.80% on average. This is quite bad

EPS 1Y (TTM)-29.32%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.35%

Revenue 1Y (TTM)-75.86%

Revenue growth 3Y1.38%

Revenue growth 5Y-28.8%

Sales Q2Q%-79.85%

3.2 Future

IPH is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.32% yearly.

IPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.06% yearly.

EPS Next Y-32.84%

EPS Next 2Y-10.27%

EPS Next 3Y-3.32%

EPS Next 5YN/A

Revenue Next Year-26.21%

Revenue Next 2Y3.05%

Revenue Next 3Y2.41%

Revenue Next 5Y43.06%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPH. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPH. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as IPH's earnings are expected to decrease with -3.32% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-10.27%

EPS Next 3Y-3.32%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for IPH!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

INNATE PHARMA SA

EPA:IPH (12/22/2025, 7:00:00 PM)

1.562

+0.03 (+1.83%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-13 2025-11-13/bmo

Earnings (Next)03-26 2026-03-26/amc

Inst Owners10.45%

Inst Owner ChangeN/A

Ins Owners0.92%

Ins Owner ChangeN/A

Market Cap143.96M

Revenue(TTM)6.00M

Net Income(TTM)-46.00M

Analysts80

Price Target4.99 (219.46%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-8.56%

PT rev (3m)-11.45%

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-248.41%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-72.88%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	23.99
P/FCF	N/A
P/OCF	N/A
P/B	28.79
P/tB	28.79
EV/EBITDA	N/A

EPS(TTM)-0.55

EYN/A

EPS(NY)-0.5

Fwd EYN/A

FCF(TTM)-0.45

FCFYN/A

OCF(TTM)-0.44

OCFYN/A

SpS0.07

BVpS0.05

TBVpS0.05

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-49.46%
ROE	-894.94%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	49.52%
FCFM	N/A

ROA(3y)-25.47%

ROA(5y)-23.4%

ROE(3y)-225.59%

ROE(5y)-153.39%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.49%

GM growth 5Y-4.49%

F-Score1

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	11.63
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	10.9%
Cap/Sales	2.83%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.24
Quick Ratio	2.24
Altman-Z	-6.39

F-Score1

WACC6.46%

ROIC/WACCN/A

Cap/Depr(3y)22.75%

Cap/Depr(5y)23.43%

Cap/Sales(3y)3.29%

Cap/Sales(5y)8.21%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-29.32%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.35%

EPS Next Y-32.84%

EPS Next 2Y-10.27%

EPS Next 3Y-3.32%

EPS Next 5YN/A

Revenue 1Y (TTM)-75.86%

Revenue growth 3Y1.38%

Revenue growth 5Y-28.8%

Sales Q2Q%-79.85%

Revenue Next Year-26.21%

Revenue Next 2Y3.05%

Revenue Next 3Y2.41%

Revenue Next 5Y43.06%

EBIT growth 1Y-30.65%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year68.86%

EBIT Next 3Y68.81%

EBIT Next 5YN/A

FCF growth 1Y-26.95%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-30.51%

OCF growth 3YN/A

OCF growth 5YN/A

INNATE PHARMA SA / IPH.PA FAQ

Can you provide the ChartMill fundamental rating for INNATE PHARMA SA?

ChartMill assigns a fundamental rating of 1 / 10 to IPH.PA.

What is the valuation status of INNATE PHARMA SA (IPH.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA (IPH.PA). This can be considered as Overvalued.

Can you provide the profitability details for INNATE PHARMA SA?

INNATE PHARMA SA (IPH.PA) has a profitability rating of 0 / 10.

How financially healthy is INNATE PHARMA SA?

The financial health rating of INNATE PHARMA SA (IPH.PA) is 2 / 10.

INNATE PHARMA SA (IPH.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

INNATE PHARMA SA / IPH.PA FAQ

Can you provide the ChartMill fundamental rating for INNATE PHARMA SA?

What is the valuation status of INNATE PHARMA SA (IPH.PA) stock?

Can you provide the profitability details for INNATE PHARMA SA?

How financially healthy is INNATE PHARMA SA?